

SPECIALTY LABORATORIES INC
Form SC 13E3/A
February 15, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13E-3

RULE 13e-3 TRANSACTION STATEMENT

Under Section 13(e) of the Securities Exchange Act of 1934

(Amendment No. 3)

SPECIALTY LABORATORIES, INC.

(Name of the Issuer)

Specialty Laboratories, Inc.

AmeriPath Group Holdings, Inc.

AmeriPath Holdings, Inc.

AmeriPath, Inc.

Welsh, Carson, Anderson & Stowe IX, L.P.

WCAS IX Associates LLC

Specialty Family Limited Partnership

James B. Peter

Deborah A. Estes

(Names of Persons Filing Statement)

Edgar Filing: SPECIALTY LABORATORIES INC - Form SC 13E3/A

Common Stock, no par value

(Title of Class of Securities)

84749R100

(CUSIP Number of Class of Securities)

Specialty Laboratories, Inc.

27027 Tourney Road

Valencia, California 91355

Attention: Jarod T. Moss

Tel: (561) 712-7383

Welsh, Carson, Anderson &

Stowe IX, L.P.

320 Park Avenue, Suite 2500

New York, New York 10022

Attention: D. Scott Mackesy

Tel: (212) 893-9500

Specialty Family Limited

Partnership

c/o Specialty Laboratories, Inc.

27027 Tourney Road

Valencia, California 91355

Attention: James B. Peter

(800) 421-7110

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Persons Filing Statement)

Copies to:

Spencer D. Klein, Esq.

Gregory D. Puff, Esq.

O Melveny & Myers LLP

Times Square Tower

7 Times Square

New York, New York 10036

Tel: (212) 326-2000

Othon A. Prounis, Esq.

Ropes & Gray LLP

45 Rockefeller Plaza

New York, New York 10111

Tel: (212) 841-5700

Theodore A. Guth, Esq.

Guth Christopher LLP

10866 Wilshire Blvd., Ste. 1250

Los Angeles, California, 90024

Tel: (310) 234-6939

This statement is filed in connection with (check the appropriate box):

- a. The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14-C or Rule 13e-3(c) under the Securities Exchange Act of 1934.
- b. The filing of a registration statement under the Securities Act of 1933.
- c. A tender offer.
- d. None of the above.

Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies:

Check the following box if the filing is a final amendment reporting the results of the transaction:

Calculation of Filing Fee

Proposed Maximum Aggregate Value of Transaction*
\$207,136,462.00

Amount Of Filing Fee**
\$24,379.96

* Calculated solely for purposes of determining the filing fee. The transaction value was determined based on the sum of (a) an aggregate cash payment of \$197,601,437.00 for the proposed per share cash payment of \$13.25 for 14,913,316 outstanding shares of common stock and (b) an aggregate cash payment of \$9,535,025.00 to holders of unvested shares of common stock and outstanding options to purchase common stock with an exercise price less than \$13.25 per share.

** The filing fee, calculated in accordance with Exchange Act Rule 0-11(c)(1), was calculated by multiplying the transaction value by 0.0001177.

- x Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$24,379.96

Form or Registration No.: Preliminary Proxy Statement

Filing Party: Specialty Laboratories, Inc.

Edgar Filing: SPECIALTY LABORATORIES INC - Form SC 13E3/A

Date Filed: November 4, 2005

- 2 -

Introduction

This Amendment No. 3 (this *Final Amendment*) to the Rule 13E-3 Transaction Statement on Schedule 13E-3 originally filed with the Securities and Exchange Commission (the *SEC*) on November 4, 2005 (as amended, the *Statement*) is being filed with the SEC by the following persons: (a) Specialty Laboratories, Inc., a California corporation (the *Issuer*); (b)(i) AmeriPath Group Holdings, Inc., a Delaware corporation (*Group Holdings*), (ii) AmeriPath Holdings, Inc., a Delaware corporation (*Holdings*), (iii) AmeriPath, Inc., a Delaware corporation (*AmeriPath*), (iv) Welsh, Carson, Anderson & Stowe IX, L.P., a Delaware limited partnership (*Welsh Carson*), and (v) WCAS IX Associates LLC, a Delaware limited liability company; and (c) James B. Peter (a former member of the *Issuer's* board of directors), Deborah A. Estes (a former member of the *Issuer's* board of directors), and the Specialty Family Limited Partnership. This *Final Amendment* is being filed pursuant to Rule 13E-3 to amend and supplement the *Statement* and report the results of the transaction which is the subject of the *Statement*.

This *Final Amendment* relates to the Agreement and Plan of Merger (as amended, the *Merger Agreement*), dated as of September 29, 2005, among *Holdings*, AmeriPath, the *Issuer* and Silver Acquisition Corp., a California corporation and a wholly owned subsidiary of AmeriPath (*Acquisition Corp.*), pursuant to which *Acquisition Corp.* was merged with and into the *Issuer* with the *Issuer* continuing as the surviving corporation (the *Merger*). Simultaneously with the execution of the *Merger Agreement*, *Holdings*, *Group Holdings*, Aqua Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of *Group Holdings*, *Welsh Carson* and certain other stockholders of *Holdings* and certain stockholders of the *Issuer* entered into a Subscription, Merger and Exchange Agreement (as amended, restated or otherwise modified, the *SME Agreement*). The Specialty Family Limited Partnership and certain other affiliates of James B. Peter and members of the Peter family were stockholders of the *Issuer* that were party to the *SME Agreement* (collectively, the *continuing investors*). Pursuant to the *SME Agreement*, among other things, (a) *Group Holdings* issued shares of common stock to *Welsh Carson* and certain of the other stockholders of *Holdings* in exchange for cash and shares of *Holdings* common stock, (b) *Group Holdings* issued shares of common stock to the *continuing investors* in exchange for a portion of the shares of the *Issuer's* common stock held by the *continuing investors*, and (c) Aqua Acquisition Corp. was merged with and into *Holdings*, with *Holdings* continuing as the surviving corporation. Simultaneously with the execution of the *Merger Agreement*, *Holdings*, the *continuing investors* and certain affiliates of the *continuing investors* entered into a voting agreement (the *Voting Agreement*) pursuant to which, among other things, the *continuing investors* and such affiliates agreed to vote in favor of the *Merger* and to vote against competing transactions unless the *Merger Agreement* is terminated.

Item 15. Additional Information **Regulation M-A Item 1011 (b)**

Item 15(b) is hereby amended and supplemented to include the following:

(b) **Other Material Information.** On January 30, 2006, at a special meeting of the *Issuer's* stockholders, (i) the holders of a majority of the outstanding shares of common stock of the *Issuer* entitled to vote and (ii) the holders of a majority of the outstanding shares of common stock of the *Issuer* not held by the *continuing investors* or their affiliates or by the directors of the *Issuer* voted affirmatively to approve the *Merger Agreement* and the *Merger*.

On January 31, 2006, the *Merger* and the transactions contemplated by the *SME Agreement* were consummated. At the effective time of the *Merger*, each share of the *Issuer's* common stock issued and outstanding (other than shares held in the treasury of the *Issuer*, shares held by *Holdings* or any direct or indirect wholly owned subsidiary of *Holdings* or the *Issuer* or held by stockholders who were entitled to and who properly exercised dissenters' rights under California law) was converted into the right to receive \$13.25 in cash. In addition, each option under the *Issuer's* stock option plans, except as provided in an applicable agreement with the optionee, was canceled in exchange for an amount in cash determined by multiplying (i) the excess of \$13.25 over the per share exercise price of the option by (ii) the number of shares of the *Issuer's* common stock subject to the option, less applicable withholding taxes. All unvested shares of the *Issuer's* common stock issued and outstanding immediately prior to the effective time of the *Merger* became fully vested as of the effective time of the *Merger*. Upon completion of the *Merger*, current stockholders of the *Issuer*, other than the *continuing investors*,

ceased to have ownership interests in the Issuer or rights as stockholders. Upon consummation of the transactions contemplated by the SME Agreement and the Merger Agreement, the Issuer became a wholly owned subsidiary of AmeriPath and Holdings, the parent company of AmeriPath, became a wholly owned subsidiary of Group Holdings. Group Holdings is owned by Welsh Carson, its co-investors, the continuing investors and certain other former stockholders of Holdings.

On February 6, 2006, the Issuer filed a Form 15 with the SEC in order to deregister its common stock under the Securities Exchange Act of 1934, as amended.

Item 16. Exhibits
Regulation M-A Item 1016 (a)

Item 16 is hereby amended and supplemented by the addition of the following exhibit thereto:

- (a)(7) Press release issued by AmeriPath, Inc., dated as of January 31, 2006, incorporated herein by reference to the Current Report on Form 8-K filed by AmeriPath, Inc. with the Securities and Exchange Commission on February 3, 2006.

SIGNATURES

After due inquiry and to the best knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

SPECIALTY LABORATORIES, INC.

By: /s/ David L. Redmond
Name: David L. Redmond
Title: Vice President

AMERIPATH HOLDINGS, INC.

By: /s/ David L. Redmond
Name: David L. Redmond
Title: Chief Financial Officer

AMERIPATH GROUP HOLDINGS, INC.

By: /s/ David L. Redmond
Name: David L. Redmond
Title: Chief Financial Officer

AMERIPATH, INC.

By: /s/ David L. Redmond
Name: David L. Redmond
Title: Chief Financial Officer

WELSH, CARSON, ANDERSON & STOWE IX, L.P.

By: WCAS IX Associates LLC, its General Partner

By: /s/ Paul B. Queally
Name: Paul B. Queally
Title: Manager

WCAS IX ASSOCIATES LLC

By: /s/ Paul B. Queally
Name: Paul B. Queally
Title: Manager

JAMES B. PETER, M.D.

/s/ James B. Peter, M.D.

DEBORAH A. ESTES

/s/ Deborah A. Estes

SPECIALTY FAMILY LIMITED PARTNERSHIP

By: /s/ James B. Peter, M.D.

Name: James B. Peter, M.D.

Title: Managing General Partner (as co-trustee of the Peter Family Revocable Trust)

By: /s/ Joan C. Peter

Name: Joan C. Peter

Title: General Partner (as co-trustee of the Peter Family Revocable Trust)

By: /s/ Deborah A. Estes

Name: Deborah A Estes

Title: General Partner

EXHIBIT INDEX

- (a)(1) Letter to Stockholders of Specialty Laboratories, Inc., incorporated herein by reference to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (a)(2) Notice of Special Meeting of the Stockholders of Specialty Laboratories, Inc., incorporated herein by reference to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (a)(3) Preliminary Proxy Statement of Specialty Laboratories, Inc., incorporated herein by reference to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (a)(4) Form of Proxy Card, incorporated herein by reference to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (a)(5) Press release issued by Specialty Laboratories, Inc. dated as of September 30, 2005, incorporated herein by reference to the Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on September 30, 2005.
- (a)(6) Certain preliminary draft presentation materials dated July 12, 2005, provided to the Special Committee and the Board of Directors of Specialty Laboratories, Inc. on September 28, 2005.
- (a)(7) Press release issued by AmeriPath, Inc., dated as of January 31, 2006, incorporated herein by reference to the Current Report on Form 8-K filed by AmeriPath, Inc. with the Securities and Exchange Commission on February 3, 2006.
- (b)(1) Commitment Letter dated as of September 29, 2005 by and among AmeriPath, Inc., Wachovia Bank, National Association, Wachovia Capital Markets, LLC, Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Deutsche Bank Trust Company Americas and UBS Loan Finance LLC.
- (c)(1) Opinion of J.P. Morgan Securities Inc. dated as of September 29, 2005, incorporated herein by reference to Appendix B to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (c)(2) Presentation of J.P. Morgan Securities Inc. to the Board of Directors of Specialty Laboratories, Inc. dated as of September 28, 2005.
- (d)(1) Agreement and Plan of Merger dated as of September 29, 2005 among AmeriPath Holdings, Inc., AmeriPath, Inc. Specialty Laboratories, Inc. and Silver Acquisition Corp., incorporated herein by reference to Appendix A to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (d)(2) Voting Agreement dated as of September 29, 2005 among AmeriPath Holdings, Inc. and the continuing investors, incorporated herein by reference to Appendix D to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (d)(3) Subscription, Merger and Exchange Agreement dated as of September 29, 2005 among AmeriPath Holdings, Inc., AmeriPath Group Holdings, Inc., Aqua Acquisition Corp., certain stockholders of AmeriPath Holdings, Inc. party thereto and certain stockholders of Specialty Laboratories, Inc. party thereto, incorporated herein by reference to Appendix E to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.

- (f)(1) Chapter 13 of the California General Corporation Law, incorporated herein by reference to Appendix C to the Proxy Statement on Schedule 14A filed by Specialty Laboratories, Inc. with the Securities and Exchange Commission on December 23, 2005.
- (g)(1) None.
- (h)(1) None.